TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7979888
Drug: Pharmacotherapy (desipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (desipramine hydrochloride)
Study: 28851188
Drug: Nicorandil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (10 mg orally before PCI and 15 mg/d for 3 days)
Study: 25389256
Drug: Atazanavir/ritonavir 300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir 300/100 mg
Study: 21612894
Drug: 25 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/kg/day amikacin
Study: 21612894
Drug: 30 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg/day amikacin
Study: 21612894
Drug: 15 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg/day (historical standard dose)
Study: 18848318
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (retinyl palmitate) 0.05% eye drops, four times daily
Study: 18848318
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A 0.05% eye drops, twice daily
Study: 16817814
Drug: Cortisol (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (0.15 mg/kg)
Study: 16817814
Drug: Corticosterone (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosterone (0.15 mg/kg)
Study: 16817814
Drug: Corticosterone (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosterone (0.04 mg/kg)
Study: 11313301
Drug: Intravenous cyclosporine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclosporine, 4 mg x kg(‐1) x day(‐1)
Study: 11313301
Drug: Methylprednisolone, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone, 40 mg/day
Study: 9257745
Drug: Piperacillin plus
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperacillin plus Gentamicin (P+G)
Study: 8292833
Drug: Commercial Western-style
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial Western-style medicine (placebo)
Study: 29500567
Drug: Target-CF 15
Normalized name: californium Cf-249
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target-CF 15 g (G1)
Study: 29500567
Drug: Target-CF 10
Normalized name: propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Target-CF 10 g (G2)
Study: 12660684
Drug: HeartBar (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HeartBar (3.3 g L-arginine, consumed twice daily for 2 weeks)
Study: 12660684
Drug: Placebo bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bar (consumed twice daily for 2 weeks)
Study: 1491124
Drug: Ipriflavone 600
Normalized name: IPRIFLAVONE
DrugBank: Ipriflavone (DB13618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipriflavone 600 mg and 1,000 mg daily (administered in three divided doses)
Study: 1491124
Drug: Conjugated estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogen (CE) 0.625 mg/day
Study: 4037631
Drug: 10% aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% aqueous solution of povidone-iodine (Betadine)
Study: 19901117
Drug: Dose-dense epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense epirubicin and cyclophosphamide followed by Paclitaxel (EC/T)
Study: 16136469
Drug: High-dose vCP1452
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vCP1452 (10^8.0 TCID50)
Study: 16136469
Drug: Regular-dose vCP1452
Normalized name: Insulina regular
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regular-dose vCP1452 (10^7.26 TCID50)
Study: 7776501
Drug: Supplementary vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementary vitamin E intake within the drug group
Study: 111945
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of xylose
Study: 111945
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of sodium chloride
Study: 111945
Drug: Nasal administration
Normalized name: Novel Influenza-H1N1-09, live virus for nasal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal administration of small amounts of vasopressin
Study: 111945
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of sodium chloride with beef-meal
Study: 31879124
Drug: Booster Immunization
Normalized name: Sanofi Pasteur COVID-19 Vaccine, Adjuvanted For Booster Immunization PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster Immunization group (BI) - received a single dose of OCV after 3 years
Study: 31879124
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (Primary Immunization group: PI) - did not receive a booster dose
Study: 19637104
Drug: Zonisamide 100
Normalized name: zonisamide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide 100 mg
Study: 18041300
Drug: Influenza vaccination
Normalized name: Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine Injection [PedvaxHIB]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccination (VAXIGRIP(R) 2003 Southern hemisphere formulation)
Study: 3545931
Drug: Combined insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined insulin plus sulfonylurea (gliclazide 40 to 240 mg daily for 12 months)
Study: 3545931
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment only (control group)
Study: 30850455
Drug: Moisturizers with
Normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moisturizers with high water: oil ratios (ie, lotions)
Study: 30850455
Drug: Moisturizers with
Normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moisturizers with low water:oil content (ie, ointments)
Study: 24874588
Drug: Surfactant-containing saline
Normalized name: surfactant protein-D homotrimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant-containing saline solution (group 1)
Study: 21916358
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine gel (CG)
Study: 21916358
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine spray (CS)
Study: 21916358
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo gel (PG)
Study: 21916358
Drug: placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo spray (PS)
Study: 16428906
Drug: Concurrent myofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent myofeedback (feedback provided immediately during the trial)
Study: 15207760
Drug: Cyclic therapy
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic therapy with etidronate (CTE) - 400 mg/day oral etidronate for 2 weeks followed by 12 weeks of 500 mg/day calcium lactate, repeated every 14 weeks (early-etidronate group)
Study: 15207760
Drug: Cyclic therapy
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic therapy with etidronate (CTE) - initiated after 18 months of no treatment (late-etidronate group)
Study: 11152831
Drug: MULTI-LINK (ML)
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: MULTI-LINK (ML) stent
Study: 9652995
Drug: Testosterone enanthate,
Normalized name: Testosterone Enanthate, enanthate 200 mg/mL intramuscular solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate, 300 mg, intramuscularly every 3 weeks for 6 months
Study: 8158680
Drug: Initial chemotherapy
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial chemotherapy (cisplatin and infusional fluorouracil) followed by loco-regional treatment (group A, n = 118)
Study: 8158680
Drug: Initial chemotherapy
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial chemotherapy (cisplatin and infusional fluorouracil) followed by loco-regional treatment (group A)
Study: 8158680
Drug: Loco-regional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loco-regional treatment alone (group B, n = 119)
Study: 8158680
Drug: Loco-regional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loco-regional treatment alone (group B)
Study: 3045792
Drug: Diazepam (DZ)
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam (DZ) 10-15 mg
Study: 3045792
Drug: Indomethacin (IM)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin (IM) 50 mg and 100 mg
Study: 3045792
Drug: Indomethacin (IM)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin (IM) 50 mg and 100 mg + Diazepam (DZ) 10-15 mg
Study: 30212845
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo (two placebo tablets twice a day for 10 days)
Study: 27760533
Drug: TOBY therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOBY therapy + therapy as usual
Study: 27760533
Drug: therapy as
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: therapy as usual
Study: 23001704
Drug: Boceprevir 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boceprevir 800 mg every 8 hours for 9 days plus a single dose of raltegravir 400 mg on day 10
Study: 23001704
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg alone
Study: 16995864
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg BIW etanercept for 24 weeks (Study 1)
Study: 16995864
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg BIW etanercept for 12 weeks (Study 2)
Study: 16995864
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg BIW etanercept for 12 weeks (Study 2)
Study: 16995864
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg QW etanercept for 24 weeks (Study 3)
Study: 16995864
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg BIW etanercept for 24 weeks (Study 3)
Study: 16995864
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg BIW etanercept for 24 weeks (Study 3)
Study: 11526374
Drug: Aminophylline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (6 mg/kg IV)
Study: 3284830
Drug: carbocysteine-sobrerol combination
Normalized name: carbocysteine / sobrerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: carbocysteine-sobrerol combination
Study: 26233732
Drug: Febuxostat 40mg
Normalized name: FEBUXOSTAT 40MG TAB
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 40mg once daily for 6 months
Study: 23438800
Drug: Interscalene group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene group (IG) received 30 mL of 0.33% levobupivacaine with adrenalin 1:200,000.
Study: 23438800
Drug: Selective group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective group (SG) received 15 mL of 0.33% levobupivacaine on each nerve (suprascapular and axillary).
Study: 12542554
Drug: Vitamin B‐12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B‐12 injection treatment
Study: 10213011
Drug: Irinotecan 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 350 mg/m2
Study: 7428803
Drug: Intravenous ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ampicillin (500 mg)
Study: 7428803
Drug: Oral ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ampicillin (500 mg)
Study: 25548079
Drug: 3 weekly
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 weekly intra‐articular injections of hyaluronic acid (HA)
Study: 20368393
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg laninamivir octanoate
Study: 20368393
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg laninamivir octanoate
Study: 20936975
Drug: oseltamivir (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: oseltamivir (75 mg, administered orally twice daily for 5 days)
Study: 18779299
Drug: Flax oil
Normalized name: Flax oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flax oil (2.4 g/d)
Study: 18779299
Drug: Flax oil
Normalized name: Flax oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flax oil (3.6 g/d)
Study: 18779299
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (0.6 g/d)
Study: 18779299
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (1.2 g/d)
Study: 18779299
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil (1 g/d)
Study: 7477800
Drug: Combined cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined cognitive‐behavioral therapy, nutritional counselling and antidepressant drugs (nortriptyline for 7, fluoxetine for 15)
Study: 1953053
Drug: Cervagem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervagem (1 mg gemeprost pessary)
Study: 25391252
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day Pycnogenol®
Study: 21276217
Drug: Educational program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational program for primary prevention of WMSD (six consecutive weekly sessions)
Study: 19550287
Drug: Dapivirine vaginal
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapivirine vaginal gel (0.001, 0.002, 0.005, or 0.02%)
Study: 19550287
Drug: Dapivirine vaginal
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapivirine vaginal gel (0.02%)
Study: 19550287
Drug: Dapivirine vaginal
Normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapivirine vaginal gel
Study: 11431597
Drug: Programmable insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Programmable insulin pump
Study: 11431597
Drug: Non-programmable insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-programmable insulin pump
Study: 8090301
Drug: Flunitrazepam 2
Normalized name: flunitrazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 2 mg (group F)
Study: 8090301
Drug: Trazodone 50
Normalized name: traZODone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone 50 mg (group T)
Study: 31115844
Drug: Vinorelbine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine monotherapy
Study: 24379454
Drug: Standardized music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized music therapy anger management program
Study: 24123845
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone and Nestorone treatment after 4 weeks
Study: 17881423
Drug: Twice-Normal Saline
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-Normal Saline (2NS)
Study: 8618474
Drug: High-dose ara-C
Normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High-dose ara-C (HIDAC)
Study: 8618474
Drug: Standard induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard induction treatment (implied control)
Study: 1579228
Drug: Intrathecal thyrotropin-releasing
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal thyrotropin-releasing hormone (TRH)
Study: 4081627
Drug: Maprotiline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (1 mg/kg/h for 60 min, then 2 mg/kg/h until 180 min)
Study: 18634956
Drug: Neuro-reflexotherapy intervention
Normalized name: MV Neuro
DrugBank: MV-NB-02 (DB17305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuro-reflexotherapy intervention (NRT) - 2 treatments, one immediately after baseline assessment and another 45 days later.
Study: 8564883
Drug: Propranolol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (60 mg for females, 80 mg for males)
Study: 12282175
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of RU 486 + 500 mg of sulprostone (Nalador) administered intramuscularly
Study: 6459357
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 60 micrograms ipratropium bromide and 200 micrograms of fenoterol
Study: 6459357
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose combinations or either drug alone
Study: 24473704
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc supplementation for 8 weeks
Study: 24473704
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc supplementation (Group A)
Study: 20835926
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of stenting and external beam radiotherapy (Group II)
Study: 21146675
Drug: Clopidogrel (started
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (started after surgery for 30 days) + Aspirin 81 mg daily
Study: 21146675
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Aspirin 81 mg daily
Study: 21146675
Drug: Clopidogrel +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel + Aspirin 81 mg daily
Study: 17923056
Drug: Topical glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glyceryl trinitrate treatment
Study: 11915041
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose peginterferon alfa-2b (3 microg/kg for 1 week, 1.5 microg/kg for 3 weeks, and 1.0 microg/kg for 44 weeks) plus 800 mg ribavirin daily
Study: 11915041
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose peginterferon alfa-2b (0.5 microg/kg for 48 weeks) plus 800 mg ribavirin daily
Study: 11915041
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose peginterferon alfa-2b
Study: 2503018
Drug: N-acetylcysteine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine 200 mg three times daily with GTN 20 mg transdermal/24 h
Study: 2503018
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with GTN 20 mg transdermal/24 h
Study: 322243
Drug: Flurbiprofen (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (150 mg daily)
Study: 790552
Drug: Aspirin (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (3.6 g daily)
Study: 27890648
Drug: Bupropion sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion sustained release (150 mg, twice a day for 12 weeks)
Study: 19817198
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy after selective posterior rhizotomy (SPR)
Study: 18184041
Drug: Quercetin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (1000 mg/day for 3 weeks)
Study: 7692455
Drug: Iloprost (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost (daily infusions of 6 hours)
Study: 7692455
Drug: PGE1 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE1 (2 x 2 hours infusions)
Study: 3285763
Drug: Verapamil (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (360 mg)
Study: 3513518
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Verapamil and Propranolol
Study: 31488098
Drug: Iron-fortified milk
Normalized name: iron succinyl milk protein complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified milk with 1.2 mg/100 mL of iron
Study: 31488098
Drug: Iron-fortified milk
Normalized name: iron succinyl milk protein complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified milk with 0.4 mg/100 mL of iron
Study: 31488098
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (1.2 mg and 0.4 mg of iron)
Study: 16484822
Drug: Autologous whole
Normalized name: Autologous whole blood product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous whole blood (AWB) injections, 8 weekly intramuscular injections
Study: 12635675
Drug: 25% aminocaproic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% aminocaproic acid (ACA) in CPM gel
Study: 12635675
Drug: 2% carboxy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% carboxy polymethylene (CPM) gel as placebo
Study: 28506956
Drug: iCBT (internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: iCBT (internet-based cognitive behavioral therapy)
Study: 27746112
Drug: Optimum intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimum intravenous busulfan AUC of 78–101 mg×h/L
Study: 27746112
Drug: Low historical
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low historical target of 58–86 mg×h/L
Study: 27746112
Drug: High busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High busulfan AUC (>101 mg×h/L)
Study: 27746112
Drug: Low AUC
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low AUC (<78 mg×h/L)
Study: 24670970
Drug: High-dose freeze-dried
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose freeze-dried strawberries (HD-FDS; 50 g/d)
Study: 24670970
Drug: Low-dose freeze-dried
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose freeze-dried strawberries (LD-FDS; 25 g/d)
Study: 24670970
Drug: High-dose control
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose control (HD-C)